Review article: Increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 9, 2007, Pages 1179-1186

  Safdi, A V ^a   Cohen, R D ^b  

^a Greater Cincinnati Gastroenterology Associates   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SIGMOIDOSCOPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; HUMANS; MESALAMINE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 35448965162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03471.x     Document Type: Review

References (38)

1. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 (2): CD000543.
2. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 (2): CD000544.
3. Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987 28 : 196 200.
4. Green JRB, Lobo AJ, Holdsworth CD, et al. and the Abacus Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998 114 : 15 22.
5. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002 97 : 1398 407.
6. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002 97 : 3078 86.
7. Pentasa® [package insert]. Wayne, PA : Shire US Inc 2007.
8. Asacol® [package insert]. Cincinnati, OH : Procter & Gamble Pharmaceuticals, Inc 2006.
9. LialdaTM [package insert]. Wayne, PA : Shire US Inc 2007.
10. Colazal® [package insert]. Morrisville, NC : Salix Pharmaceuticals, Inc 2007.
11. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
12. Pruitt R, Levine DS, Safdi M, et al. Balsalazide as alternative therapy to mesalamine dose-escalation for acute, mild to moderate ulcerative colitis. Poster presented at: Digestive Disease Week; May 19-22, 2002 San Francisco, CA.
13. Sands BE, Abreu MT, Ferry GD, et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005 11 (Suppl. 1 S22 8.
14. ® Study Group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993 88 : 1188 97.
15. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987 317 : 1625 9.
16. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991 115 : 350 5.
17. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005 100 : 2478 85.
18. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006 24 : 1087 97.
19. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75.
20. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5 : 95 102.
21. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973 289 : 491 5.
22. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002 16 : 647 62.
23. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987 93 : 1255 62.
24. Sandborn WJ, Stone CD, Papadakis KA, Ajayi FO, Nesbitt JD, Regalli G. Assessment of systemic exposure following oral administration of mesalamine as an 800 mg tablet (4.8 g/day) or a 400 mg tablet (2.4 g/day): analysis of combined data from two randomized clinical trials in patients with ulcerative colitis (abstract R.0472). Presented at: World Congress of Gastroenterology; September 10-14, 2005 Montreal, Canada.
25. Hussain FN, Ajjan RA, Riley SA. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. J Clin Pharmacol 2000 49 : 323 30.
26. Mahmud N, Weir DG, Kelleher D. Systemic levels of free 5-aminosalicyclic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Ir J Med Sci 1999 168 : 228 32.
27. Schreiber S, Hämling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997 40 : 761 6.
28. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001 7 : 221 5.
29. Kornbluth A, Cuffari C, George J, et al. A prospective, blinded assessment of distal colonic mucosal concentrations of 5-ASA and NAC-5ASA in UC patients treated with either balsalazide (Colazal) or a pH-dependent mesalamine (Asacol). Gastroenterology 2006 130 (Suppl. 2 A-209 (DDW abstract S1358).
30. Kwon H, Lionberger R, Yu LX, et al. Simulation of absorption of mesalamine from delayed release tablets (abstract C-17). Presented at: 11th Annual FDA Science Forum; April 27-28, 2005 Washington, DC.
31. Moore T, Gao Z, Westenberger BJ, et al. Dissolution testing of mesalamine delayed release tablets (abstract I-29). Presented at: 11th Annual FDA Science Forum; April 27-28, 2005 Washington, DC.
32. Ewe K, Schwartz S, Petersen S, Press AG. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci 1999 44 : 1434 9.
33. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993 38 : 1989 93.
34. Nugent SG, Kumar D, Rampton DS, Yazaki E, Evans DF. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA-containing capsules (abstract T34). Gut 2000 46 (Suppl. 2 A9.
35. Press AG, Hauptmann IA, Hauptmann L, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998 12 : 673 8.
36. Raimundo AH, Evans DF, Rogers J, Silk DBA. Gastrointestinal pH profiles in ulcerative colitis (abstract). Gastroenterology 1992 102 : A681.
37. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-Profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989 3 : 605 13.
38. Safdi A, Safdi M. Determination of 5-ASA in whole or partial mesalamine delayed-release tablets recovered from fecal samples of healthy volunteers: do 5-ASA delivery systems matter in the treatment of ulcerative colitis? Poster presented at: American College of Gastroenterology 70th Annual Scientific Meeting; October 28-November 2, 2005 Honolulu, HI.